The elderly are among the groups at highest risk for the serious complications of influenza that can result in hospitalization or death. We conducted a cost benefit and cost effectiveness analysis of influenza vaccination among the elderly. In the economic models we incorporated new information on the benefits of vaccination in reducing hospitalizations for heart disease and stroke, in addition to previously known benefits of vaccination in reducing hospitalizations for pneumonia, influenza and other respiratory conditions. The model took the perspective of the health care payer. Monte Carlo simulation was used to estimate the net costs or savings associated with vaccination. The results of the cost benefit analysis indicated that vaccination would result in net savings of $71 for each elderly person vaccinated (5th to 95th percentiles, $32 to $119 in savings). Vaccination resulted in the prevention of 9 deaths per 1000 persons vaccinated, which translated into net savings of $810 per life-year gained. The findings from this study lend additional support to policies and programs that promote routine influenza vaccination of all persons 65 years and older.
- Cost effectiveness